Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Millán José Luis) > Bispecific antibody...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		03002naa a2200313 4500
001		oai:DiVA.org:umu-44795
003		SwePub
008		110610s1999 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-447952 URI
040		a (SwePub)umu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Smans, Karine Au Umeå universitet,Medicinsk och klinisk genetik4 aut
245	1 0	a Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens
264	1	c 1999
338		a print2 rdacarrier
520		a We have shown previously that a bispecific antibody (BsAb) directed against both germ-cell alkaline phosphatase (GCAP) and the CD3 complex on mouse T cells could effectively eliminate GCAP-positive tumor cells in vivo using an immunocompetent mouse model. However, some GCAP-negative tumor cells were still able to grow, suggesting that BsAb therapy, when used in a clinical setting, could benefit from targeting several tumor markers to prevent outgrowth of tumor cells lacking a targeted marker. To test this hypothesis, we developed an in vitro model based on primary human ovarian carcinoma (OC) cultures and BsAbs directed against human T cells and several tumor markers [placental alkaline phosphatase (PLAP), GCAP, folate-binding protein (FBP) and CA19.9]. OC cells, isolated from primary tumors, were co-cultured with human peripheral blood mononuclear cells in the presence or absence of various concentrations of BsAbs against PLAP/GCAP, FBP and CA19.9 administered separately or in combination. Results derived from 18 primary OC samples showed that the combination treatment was better than or equally effective as the best single BsAB treatment in 60% of cases. Sometimes targeting FBP, PLAP/GCAP or CA19.9 alone was superior to targeting all simultaneously. Combining each BsAb with a low dose of IL-2 was always beneficial. These results indicate that before using a specific BsAb in the clinic, it is important to determine the optimal BsAb for each patient using this in vitro assay on cells from the removed tumor mass.
700	1	a Ingvarsson, Magdalenau Umeå universitet,Obstetrik och gynekologi4 aut0 (Swepub:umu)mata0002
700	1	a Lindgren, Peteru Umeå universitet,Obstetrik och gynekologi4 aut
700	1	a Canevari, Silvana4 aut
700	1	a Walt, Heinrich4 aut
700	1	a Stigbrand, Torgnyu Umeå universitet,Klinisk immunologi4 aut0 (Swepub:umu)tost0001
700	1	a Bäckström, Torbjörnu Umeå universitet,Obstetrik och gynekologi4 aut0 (Swepub:umu)toba0001
700	1	a Millán, José Luisu Umeå universitet,Medicinsk och klinisk genetik4 aut
710	2	a Umeå universitetb Medicinsk och klinisk genetik4 org
773	0	t International Journal of Cancerg 83:2, s. 270-277q 83:2<270-277x 0020-7136x 1097-0215
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-44795

Hitta via bibliotek

International Journal of Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Smans, Karine A; Ingvarsson, Magd ...; Lindgren, Peter; Canevari, Silvan ...; Walt, Heinrich; Stigbrand, Torgn ...; visa fler...; Bäckström, Torbj ...; Millán, José Lui ...; visa färre...

Artiklar i publikationen: International Jo ...

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se